Albert Bourla, Pfizer CEO (AP Images)
November 17, 2021 07:08 AM EST
Coronavirus

Covid-19 pill could add an­oth­er $15-25B to Pfiz­er's al­ready tor­rid pan­dem­ic cash flow — an­a­lyst

Amber Tong

If you thought Pfiz­er was rak­ing it in with megablock­buster sales of its BioN­Tech-part­nered Covid-19 vac­cine — last pro­ject­ed at $36 bil­lion for 2021 — think again …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times